To address the growing U.S. shortages of critical generic drugs, long-term remedies, both legislative and regulatory, must be considered. Some basic changes in generic-drug law and FDA practices and greater financial incentives for manufacturing generics may be key.
No takes yet. Share an insight, caveat, or question.
Bruce A. Chabner (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: